PharmaShots | Incisive News in 3 Shots

Subscribe Now

Subsidiary

Mallinckrodt to Divest its Subsidiary BioVectra for $250M

Mallinckrodt to Divest its Subsidiary BioVectra for $250M

September 10, 2019

Gilead's subsidiary Asegua Therapeutics Plans to Launch Authorized Generic Versions in the US of Epclusa & Harvoni for the Treatment of Chronic Hepatitis C

Gilead's subsidiary Asegua Therapeutics Plans to Launch Authorized Generic Versions in the US of Epclusa & Harvoni for the Tre...

September 24, 2018

Contact Us

First Floor, B-66, Sector 63 Noida, Uttar Pradesh, INDIA - 201301
+91-120 428 0707
connect@pharmashots.com
Newsletter

Our Information

Follow Us